Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | EEF2K | O00418 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926591 | 0.88 | KIFC1 (0.53) | MAPK14GPR34RXFP1KIFC1 | |
| SCHEMBL5926247 | 0.88 | CYP26A1 (0.48) | CTSACYP26A1 | |
| SCHEMBL5927140 | 0.88 | CYP26A1 (0.46) | CTSAFFAR1CYP26A1RXFP1 | |
| SCHEMBL5927463 | 0.87 | CYP26A1 (0.42) | CTSACYP26A1MMP12 | |
| SCHEMBL5926736 | 0.87 | POLB (0.43) | CTSACYP26A1 | |
| SCHEMBL5926345 | 0.86 | CYP26A1 (0.42) | CTSAFFAR1CYP26A1MMP12 | |
| SCHEMBL5927339 | 0.84 | CTSA (0.43) | CTSACYP26A1RXFP1 | |
| SCHEMBL5926381 | 0.83 | IGF2BP2 (0.48) | FFAR1CYP26A1MMP12EEF2K | |
| SCHEMBL5927217 | 0.79 | CTSA (0.47) | CTSAFFAR1CYP26A1RXFP1KIFC1 | |
| SCHEMBL5926181 | 0.79 | IGF2BP2 (0.52) | CTSAFFAR1MAPK14MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | CTSA 426/4885FFAR1 1360/4885MAPK14 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.